UnknownNot Applicable

Study of the Impact of Fatty Acids From Seal Oil on the Relief of Symptoms Associated With Rheumatoid Arthritis

Canada130 participantsStarted 2022-01-20

Plain-language summary

This project proposes to conduct the first fully controlled and randomized clinical study demonstrating the impact of DPA-rich sea bass oil on the reduction of symptoms related to rheumatoid arthritis. This unique approach will allow to clinically evaluate the benefits of sea bass oil on the relief of rheumatoid arthritis-related pain in a population suffering from inflammatory arthritis.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Have been diagnosed with RA after the age of 18; * Have had RA for at least 1 year; * Meet the 2010 ACR/EULAR criteria; * Stable disease status for at least 3 months: * Low to moderate activity as measured by the Clinical Disease Activity Index (CDAI); * Stable dose of DMARD (conventional synthetic Disease Modifying Anti-Rheumatic Drug) for at least 3 months; * Stable dose of NSAIDs and corticosteroids for at least 1 month; * Do not take \> 10 mg per day of prednisone. Exclusion Criteria: * Have been diagnosed with another rheumatologic autoimmune disease; * Have been diagnosed with inflammatory bowel disease (ulcerative colitis or Crohn's disease); * Have a disease that may interfere with the physician's assessment (e.g. severe osteoarthritis); * Have fibromyalgia; * Consume omega-3 fatty acid supplements other than those given during the project; * Have an allergy or intolerance to seafood; * Consume natural health products that may potentially affect inflammation (e.g. glucosamine, chondroitin, devil's claw, curcumin products) during the project; * Consume more than two servings (1 serving = 90 g or 3 ounces) of fish and seafood per week for the duration of the study; * Take anticoagulant medication; * Be treated or have previously received biological agents or inhibitors of JAK (Janus kinase) (family of tyrosine kinases).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Efficacy of DPA-rich seal oil in improving the clinical signs and symptoms associated with rheumatoid arthritis

Timeframe: One year after the beginning of the study

Trial details

NCT IDNCT04688398

SponsorLaval University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-08-31

Contact for this trial

Louise Corneau, MSc

418-656-2131 louise.corneau@fsaa.ulaval.ca

View on ClinicalTrials.gov More Polyarthritis trials